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Abstract
A key pathology of Alzheimer’s disease (AD) is amyloid β (Aβ) accumulation that triggers synaptic impairments and
neuronal death. Metabolic disruption is common in AD and recent evidence implicates impaired leptin function in AD. Thus
the leptin system may be a novel therapeutic target in AD. Indeed, leptin has cognitive enhancing properties and it prevents
the aberrant effects of Aβ on hippocampal synaptic function and neuronal viability. However, as leptin is a large peptide,
development of smaller leptin-mimetics may be the best therapeutic approach. Thus, we have examined the cognitive
enhancing and neuroprotective properties of known bioactive leptin fragments. Here we show that the leptin (116–130)
fragment, but not leptin (22–56), mirrored the ability of leptin to promote AMPA receptor trafﬁcking to synapses and
facilitate activity-dependent hippocampal synaptic plasticity. Administration of leptin (116–130) also mirrored the cognitive
enhancing effects of leptin as it enhanced performance in episodic-like memory tests. Moreover, leptin (116–130) prevented
hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. These ﬁndings establish further the
importance of the leptin system as a therapeutic target in AD.
Key words: Alzheimer’s disease, amyloid beta, AMPA receptor trafﬁcking, episodic memory, hippocampus, synaptic
plasticity
IntroductionQ2
Alzheimer’s disease (AD) is a complex, progressive brain dis-
order that results in profound cognitive deﬁcits, particularly in
memory. Accumulation of toxic amyloid plaques and neuroﬁb-
rillary tangles comprising hyperphosphorylated tau are key
pathological features of AD. Proteolytic processing of APP and
generation of toxic amyloid beta (Aβ) is linked to aberrant synap-
tic function and neuronal degeneration. Several studies indicate
that soluble Aβ oligomers greatly inﬂuence activity-dependent
hippocampal synaptic plasticity resulting in deﬁcits in learn-
ing and memory. Indeed, Aβ inhibits the induction of hippo-
campal long-term potentiation (LTP), but facilitates long-term
depression (LTD) (Walsh et al. 2002; Shankar et al. 2008).
Furthermore, Aβ signiﬁcantly alters AMPA receptor trafﬁcking to
and away from synapses which contributes to hippocampal syn-
aptic dysfunction (Hsieh et al. 2006; Liu et al. 2010).
Clinical evidence indicates that diet and lifestyle are major
risk factors for developing AD and disruption to metabolic sys-
tems is linked to AD (Stranahan and Mattson 2012). The meta-
bolic hormone leptin regulates energy homeostasis, but also
markedly inﬂuences hippocampal synaptic function. Indeed,
leptin-insensitive rodents exhibit impaired hippocampal LTP
and spatial memory (Li et al. 2002). Moreover, direct adminis-
tration of leptin into the hippocampus facilitates learning
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(Wayner et al. 2004), whereas hippocampal dendritic morph-
ology, glutamate receptor trafﬁcking and synaptic plasticity are
signiﬁcantly altered after leptin treatment (Shanley et al. 2001;
O’Malley et al. 2007; Moult et al. 2010; Luo et al. 2015). Clinical
studies indicate that aberrant leptin function is associated with
an increased risk of AD, as AD patients exhibit signiﬁcantly
lower leptin levels than normal (Power et al. 2001). Individuals
with lower circulating leptin also have a greater risk of develop-
ing AD (Lieb et al. 2009). Additionally, leptin levels are markedly
reduced in rodent models with familial AD mutations (APPSwe;
PSIM146V; Fewlass et al. 2004). In cellular models of AD, leptin
treatment prevents the aberrant effects of Aβ, as leptin reverses
the ability of Aβ to inhibit LTP and facilitate LTD in hippocam-
pal slices (Doherty et al. 2013) and it prevents Aβ-driven intern-
alization of the AMPA receptor subunit, GluA1 in hippocampal
neurons (Doherty et al. 2013). Chronic intracerebroventricular
injection of leptin also reverses Aβ-induced impairments in LTP
in vivo (Tong et al. 2015). In cell survival assays, leptin protects
against Aβ-induced toxicity as neuronal viability is increased
after leptin treatment. Moreover the cortical expression of 2
AD-linked biomarkers, endophilin 1 and phosphorylated tau,
are enhanced in leptin-insensitive Zucker fa/fa rats (Doherty
et al. 2013). Thus there is growing evidence that leptin-based
therapies may be beneﬁcial in AD.
However, using leptin therapeutically may not be the best
approach due to its widespread central actions. One possibility
is to develop small molecules that mimic leptin action. Indeed,
studies have found that speciﬁc fragments of the leptin peptide
are bioactive and mirror the antiobesity effects of leptin
(Grasso et al. 1997; Rozhavskaya-ArenaQ3 et al. 2000). Indeed,
application of a C-terminal fragment of leptin (amino acids
116–130) or a shorter fragment (116–121) to leptin-deﬁcient ob/
ob mice reduced food intake and body weight (Grasso et al.
1997; Rozhavskaya-Arena et al. 2000; Grasso et al. 2001).
However, another leptin fragment (22–56) is also bioactive as
signiﬁcant reductions in food intake have been observed after
leptin (22–56) administration (Samson et al. 1996). Thus, it is
feasible that different parts of the leptin molecule are active in
the CNS. However, the cognitive enhancing and neuroprotec-
tive properties of the bioactive leptin fragments are unknown.
Here we show that leptin (116–130), but not leptin (22–56), mir-
rored the effects of leptin on hippocampal synaptic plasticity
and also prevented hippocampal synaptic disruption and cell
death induced by Aβ. Moreover, leptin (116–130) has similar
cognitive enhancing effects to leptin as it enhanced episodic-
like memory. These ﬁndings establish further the importance
of the leptin system as a therapeutic target in AD.
Methods
Primary Neuronal Culture
Hippocampal cultures were prepared from neonatal Sprague
Dawley rats as before (O’Malley et al. 2007). Brieﬂy, neonatal
Sprague Dawley rats (1–3 days old) were killed by cervical dis-
location in accordance with Schedule 1 of the United Kingdom
Government Animals (Scientiﬁc Procedures) Act, 1986 and the
hippocampi removed. After washing in HEPES buffered saline
(HBS) comprising (mM): NaCl 135; KCl 5; CaCl2 1; MgCl2 1; HEPES
10; D-glucose 25 at pH 7.4; cells were treated with protease Type
X and Type XIV (0.5mg/ml; Sigma) for 25min at room tempera-
ture. Dissociated cells were plated onto sterile dishes (Falcon
3001) treated with poly-l-lysine (20 μg/ml; 1–2 h) and main-
tained in MEM with serum replacement-2 (Sigma) in a
humidiﬁed atmosphere of 5% CO2 and 95% O2 at 37°C for up to
3 weeks.
Human Neural Cell Line SH-SY5Y
The human neuroblastoma cell line, SH-SY5Y (ECACC, UK) was
maintained in Dulbecco’s Modiﬁed Eagle Medium supplemented
with glucose (4500 µg/l) and 10% (v/v) cosmic calf serum (Fisher
Scientiﬁc, UK) at 37°C in a humidiﬁed atmosphere of 5% CO2,
95% air and allowed to reach 70–80% conﬂuence before seeding.
Cells (passage 10–18) were plated at 10 000 cells per well in 96
well tissue culture plates (Nunc, VWR, UK) and at a density of
2 × 105 cells in 35mm dishes for protein extraction. To induce
differentiation, cells were cultured in DMEM supplemented with
glucose (4500 µg/l), 1% (v/v) cosmic calf serum and 10 μM retinoic
acid for 5 days. Thereafter they were incubated in DMEM supple-
mented with glucose (4500 µg/l), serum replacement 2 (2%;
Sigma, UK) and 18 μM 5-ﬂuorodeoxyuridine to inhibit prolifer-
ation of undifferentiated cells. The 50% of the medium was
changed every 2–3 days and pharmacological treatment was car-
ried out 7 days after switching to this medium. Reagents used
were (from Sigma UK unless stated) 0.1–10nM human leptin and
leptin (116–130); 0.1–10nM leptin (22–56; Bachem; Switzerland);
5 μΜ copper chloride; 10mM Aβ1–42; 5 μM WP1066 or 50 nM wort-
mannin. All treatments were added to the culture at the same
time and survival assays were carried out after 96 h treatment.
Protein samples for ELISA were extracted 3 h after exposure to
the relevant reagents.
Cell Survival Assays
The concentration of lactate dehydrogenase (LDH) in the cul-
ture medium was used to monitor the level of cell death, as
previously (Oldreive and Doherty Q42010). A Crystal violet assay
was used to assess total cell number. Cells were ﬁxed in neutral
buffered formalin and washed 3 times in PBS prior to staining
with 0.01% crystal violet acetate for 5min. Plates were washed
5–10 times in dH2O and cells solubilised in 100 μl dimethyl sulf-
oxide (DMSO) before reading the absorbance on a Biohit BP100
plate reader. For both assays, data is expressed as percentage
relative to control, untreated wells to normalize for differences
in plating density between individual experiments.
ELISA for Cell Signalling Pathways
Protein from cultures was extracted into 500 µl Tris-buffered
saline containing protease inhibitor cocktail, and a Bradford
assay used to determine protein concentration. Samples were
diluted to give equal loading onto ELISA plates. Commercially
available ELISA kits were used in accordance with the manufac-
turer’s instructions to determine the ratio of pan-STAT3 to
phospho-STAT3 (Sigma, UK) and pan-Akt to phospho-Akt
(Sigma, UK). Each protein sample was run in duplicate.
Surface Labelling of AMPA Receptors
To monitor GluA1 surface expression, immunocytochemistry was
performed on hippocampal cultures (7–14 DIV) as before (Moult
et al. 2010). Neurons were treated with agents for 20min at room
temperature (20–22°C) before incubation with an antibody against
an N-terminal region of GluA1 (sheep anti-GluR1; in house anti-
body against synthetic peptide (RTSDSRDHTRVDWKR) corre-
sponding to 253–267 residues of GluR1; 1:100; Moult et al. 2010) at
4°C. Neurons were then ﬁxed with 4% paraformaldehyde (5min)
before adding an appropriate ﬂuorescently labelled secondary
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antibody (1:250; 30min) to enable visualization of GluA1 surface
staining. No labeling was observed after incubation with second-
ary antibody alone. For synaptic colocalization studies, surface
GluA1 staining was compared with synaptophysin (antisynapto-
physin antibody) immunolabelling and percentage of surface
GluA1 at synapses was assessed as the number of GluA1-positive
sites that colocalize with synaptophysin-positive sites.
An Axiovert 200M laser scanning confocal microscope was
used for image acquisition and analysis. Dual labeling images
were obtained in multitracking mode using a 15 s scan speed.
Intensity of staining was determined ofﬂine using Lasersharp
software (Carl Zeiss). Analysis lines (50 μm) were drawn along
randomly selected dendritic regions (50 nm), and mean ﬂuores-
cence intensity was calculated. Data were obtained from at
least 4 randomly selected cells for each condition, and all data
were obtained from at least 3 different cultures from different
animals. Within a given experiment, all conditions, including
illumination intensity and photomultiplier gains, were kept
constant. To quantify experimental data obtained from separ-
ate days, data were normalized relative to mean ﬂuorescence
intensity in control neurons.
Hippocampal Slice Preparation and Electrophysiology
Parasagittal hippocampal slices (300 µm) were prepared from
either P13–21 or 12–24-week-old male Sprague Dawley rats as
previously (Moult et al. 2010). Brains were rapidly removed and
placed in ice-cold artiﬁcial CSF (aCSF; bubbled with 95% O2 and
5% CO2) containing the following (in mm): 124 NaCl, 3 KCl, 26
NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 1 MgSO4, and 10 D-glucose. Once
prepared, parasagittal slices were allowed to recover at room
temperature in oxygenated aCSF for 1 h before use. Slices were
transferred to a submerged chamber maintained at room tem-
perature and perfused with artiﬁcial cerebrospinal ﬂuid at 2ml
min−1. Standard extracellular recordings were used to monitor
evoked ﬁeld excitatory postsynaptic potentials (fEPSP) from stra-
tum radiatum. The Schaffer collateral-commissural pathway was
stimulated (constant voltage; 0.1ms) at 0.033Hz, using a stimulus
intensity that evoked a peak amplitude ∼50% of the maximum.
Synaptic potentials were low pass ﬁltered at 2 kHz and digitally
sampled at 10 kHz. The fEPSP slope was measured and expressed
relative to baseline. Synaptic records are the average of 4 con-
secutive responses and stimulus artefacts are blanked for clarity.
LTP was induced using a high frequency stimulation para-
digm (10 trains; 8 stimuli; 100 Hz), whereas the subthreshold
LTD paradigm used was low frequency stimulation (LFS; 1 Hz)
for 5min (300 shocks; 15). A primed burst stimulation paradigm
(5 trains of 8 stimuli at 100 Hz; Rose and Dunwiddie 1986) was
used to induce STP. Recordings were made using an Axopatch
200B ampliﬁer and analyzed using LTP v2.4 software (Anderson
and Collingridge 2007). In all experiments, the slope of fEPSPs
was monitored continuously. For studies comparing the actions
of leptin and the fragments on synaptic transmission, the
mean slope (average of 5min recording) of fEPSPs obtained dur-
ing the 5min period immediately prior to leptin and/or agent
addition was compared with that after 25–30min exposure to
the agent. In synaptic plasticity studies, the degree of potenti-
ation or depression was calculated 30–35min after LFS or HFS
and expressed as a percentage ofQ5 baseline ± SEM.
Episodic-Like Memory Testing
Mice were tested using the same protocol used to test object–
place-context (OPC) recognition in rats (Wilson et al. 2013).
The size of the testing box was reduced to 30 cm × 20 cm × 20 cm
and the household objects used in the task were approximately
the size of the mice in at least 1 dimension. The box could be
conﬁgured with 2 sets of contextual features (white vs. stripes)
by using different wall and ﬂoor inserts. These created one
environment that was plain white and one that had stipes and
a mesh ﬂoor. Mice were handled extensively prior to training
and then habituated to the box for 4 days before undergoing
object recognition, object–place and object–context training.
These data are not presented and served only to familiarize the
mice to the testing procedures and the factors that are manipu-
lated during the OPC task. On the OPC testing days, mice were
given IP injections of either saline, leptin or leptin (116–130,
both at 7.8 nM/ml) 30min prior to testing. Testing consisted of
3 stages; 2 sample phases and a test phase (illustrated in
Fig. 7A). Each phase was 3min duration and exploration behav-
iour was scored using custom written software (Observe,
University of St Andrews). Between all phases the box was
cleaned and dried using F10 solution. All testing was recorded
on a webcam connected to a laptop to allow ofﬂine scoring of
behaviour. Twenty percent of trials were rescored by a
researcher who was blind to the group identity of the mice and
these scores were found to be within 10% of the original scor-
ing. The dependent variable measured was a discrimination
index that is calculated by subtracting the amount of time
exploring the familiar object from the amount of time exploring
the novel object and dividing by the total amount of explor-
ation. This measure was taken from the ﬁrst minute of the test
trial as novelty discrimination has been shown to rapidly
diminish after the ﬁrst minute (Clarke Q6et al. 2000).
Statistical Analyses
In immunocytochemical studies, data are expressed as
mean ± SEM and statistical analyses performed using Q7one-way
ANOVA with Tukey’s post hoc test for comparisons between
multiple groups. In electrophysiological studies, analyses were
performed using repeated measures ANOVA for comparison
between multiple groups. A one-way ANOVA with Tukey’s post
hoc test was used for comparison between multiple groups in
cell viability assays. In ELISA assays, a t-test was used to deter-
mine differences between groups. P < 0.05 was considered sig-
niﬁcant. In behavioural studies a one-way ANOVA with Tukey’s
post hoc tests was used for comparison between the groups.
Materials
Recombinant human leptin (R&D Systems, Europe) was used
in all experiments. Leptin was prepared as a 50 µM stock solu-
tion in normal aCSF and was diluted to the required concen-
tration in aCSF or HBS. Aβ1–42 peptide was synthesized and
puriﬁed by Dr. Elliott at Yale University (New Haven, CT, USA)
based on the human Aβ sequence. The lyophilized powder
was solubilized in DMSO and diluted to a working concentra-
tion. For cell viability and biochemical assays Aβ was prepared
as described previously as Aβ has shown to elicit toxicity
when in a β sheet conformation (Simmons et al. 1994). Brieﬂy,
lypholized powder was solubilized in dH2O to a concentration
of 1mM in phosphate-buffered saline and incubated for
24 h at 37°C prior to further dilution to working concent-
ration in culture medium. Wortmannin, bisperoxovanadium
(Calbiochem), WP1066 (Cayman Chemicals), and D-AP5 (Tocris
Cookson) were all obtained commercially.
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Results
Leptin (116–130) Facilitates NMDA Receptor-Dependent
Hippocampal Synaptic Plasticity
It is known that NMDA receptors contribute little to basal exci-
tatory synaptic transmission but synaptic activation of NMDA
receptors is crucial for LTP induction at hippocampal synapses
(Bliss and Collingridge 1993). Previous studies indicate that lep-
tin enhances the magnitude of activity-dependent LTP in acute
hippocampal slices (Oomura et al. 2006) and following direct
administration into the hippocampus in vivo (Wayner et al.
2004). We have also shown that leptin facilitates NMDA
receptor-dependent synaptic plasticity as leptin promotes con-
version of short term potentiation (STP) to hippocampal LTP
(Shanley et al. 2001). In order to compare the effects of leptin
and the leptin fragments on synaptic plasticity in juvenile hip-
pocampal slices (P13–21), a primed burst stimulation paradigm
(5 trains of 8 stimuli at 100 Hz; Rose and Dunwiddie 1986) was
used to induce STP, which returned to baseline levels within
30–35min (n = 4; Fig. 1A). In accordance with previous studies
(Shanley et al. 2001), application of leptin (50 nM) prior to the
stimulation paradigm converted STP into a persistent increase
in synaptic transmission (155 ± 6.1% of baseline at 40min;
n = 4; P < 0.05; Fig. 1A). Similarly, treatment with 50 nM leptin
(116–130) facilitated synaptic plasticity as synaptic transmis-
sion was enhanced to 143 ± 6.4% of baseline in leptin (116–130)-
treated slices (n = 4; P < 0.05; Fig. 1B). In contrast, in slices
exposed to 50 nM leptin (22–56), only STP was observed as syn-
aptic transmission returned to baseline levels within 40min
(n = 6; Fig. 1C).
Leptin (116–130) Induces Synaptic Plasticity at Adult
Hippocampal CA1 Synapses
We have shown that leptin regulation of excitatory synaptic
transmission is age-dependent. Thus in contrast to its effects
in juvenile tissue, leptin (25 nM) induces a novel form of LTP in
adult hippocampus (Moult and Harvey 2011). In order to verify
if the leptin fragments mirror leptin action in adult tissue, the
effects of the leptin fragments were examined in hippocampal
slices from adult (12–24 weeks) rats. In accordance with previ-
ous studies (Moult et al. 2010; Moult and Harvey 2011),
Figure 1. Leptin (116–130) promotes conversion of STP into a persistent increase in synaptic transmission in juvenile hippocampus. (A) Pooled data showing that
primed burst stimulation (indicated by the arrow) delivered in the absence of leptin induced STP (ﬁlled circle) in juvenile hippocampal slices. In contrast, in leptin-
treated slices (open circle) the same stimulation paradigm resulted in a persistent increase in synaptic transmission. In this and subsequent ﬁgures, each point is the
average of 4 successive responses. Top, Representative synaptic records (average of 4 consecutive records) are shown for the times indicated. (B) During exposure to
leptin (116–130; 50 nM), application of the primed burst stimulation paradigm resulted in a persistent increase in synaptic transmission (B), whereas only STP was evi-
dent in slices treated with leptin (22–56; C).
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application of leptin (25 nM; 20min) to adult slices rapidly
enhanced synaptic transmission (to 188 ± 13% of baseline;
n = 4; P < 0.01; data not shown) which was sustained for the
duration of recordings. Synaptic transmission was also mark-
edly increased (to 140 ± 13% of baseline; n = 5; P < 0.05; Fig. 2A)
after treatment with 25 nM leptin (116–130), whereas applica-
tion of 25 nM leptin (22–56) had no signiﬁcant effect on synaptic
efﬁcacy (99 ± 2% of baseline; n = 4; P > 0.05; Fig. 2B). These data
indicate that leptin (116–130) mirrors the ability to leptin to
enhance synaptic efﬁcacy in adult hippocampus.
Leptin (116–130), But Not Leptin (22–56) Enhances the
Surface Expression of GluA1
Trafﬁcking of AMPA receptors to and away from synapses is
crucial for various forms of activity-dependent synaptic plasti-
city (Collingridge et al. 2004). Our studies indicate that leptin
regulates AMPA receptor trafﬁcking as leptin promotes trafﬁck-
ing of GluA1 to hippocampal synapses (Moult et al. 2010).
Moreover the ability of leptin to induce LTP in adult hippocam-
pus requires the delivery of GluA1 to synapses by leptin (Moult
et al. 2010). Thus, to assess if the leptin fragments also inﬂu-
ence AMPA receptor trafﬁcking processes, the surface expres-
sion of GluA1 was assayed in cultured hippocampal neurons
(Moult et al. 2010). In agreement with previous studies, applica-
tion of leptin (50 nM; 15min) increased surface GluA1 expres-
sion to 184 ± 7%; (n = 36; P < 0.001; Fig. 2C,D) compared with
control hippocampal neurons. Similarly GluA1 surface expres-
sion was elevated (to 160 ± 6% of control; n = 36; P < 0.001) after
exposure to 50 nM leptin (116–130; Fig. 2C,D), whereas GluA1
surface expression (98 ± 4% of control; n = 36; P > 0.05) was not
altered after treatment with 50 nM leptin (22–56). These data
indicate that leptin (116–130), but not leptin (22–56) mirrors the
plasticity enhancing effects of leptin by increasing GluA1 sur-
face expression in hippocampal neurons.
As excitatory synaptic strength is governed by the density of
AMPA receptors expressed at synapses, the effects on synaptic
AMPA receptors was examined by comparing the colocalization
between surface GluA1 and synaptophysin immunolabelling in
hippocampal cultures (Moult et al. 2010). In agreement with
previous studies (O’Malley et al. 2007; Moult et al. 2010), leptin
(50 nM; 30min) increased synaptophysin staining to 144 ± 9% of
control (n = 48; P < 0.001) and it also enhanced the degree of
colocalization between surface GluA1 and synaptophysin
immunostaining from 43 ± 5.4% to 62 ± 4.4% (n = 36; P < 0.05;
Fig. 2E). Similarly, in hippocampal neurons treated with leptin
(116–130), synaptophysin staining was increased to 122 ± 9%
(n = 36; P < 0.05) and a signiﬁcant increase (to 64 ± 4.9%; n = 36;
P < 0.01) in GluA1-synaptophysin colocalization was observed
(Fig. 2E). Conversely, exposure to leptin (22–56) had no signiﬁ-
cant effect on either synaptophysin staining (105 ± 9%; n = 36;
P > 0.05) or the degree of colocalization (49 ± 5.4%; n = 36;
P > 0.05; Fig. 2E). These data indicate that leptin (116–130), but
not leptin (22–56) promotes the trafﬁcking of GluA1 to synapses
in hippocampal neurons.
Inhibition of the phosphatase, PTEN underlies leptin-driven
trafﬁcking of GluA1 to synapses (Moult et al. 2010). In order to
determine if similar leptin dependent signalling cascades medi-
ate the actions of leptin (116–130), the effects of pharmaco-
logical inhibition of PTEN with bisperoxovanadium (bpV;
Schmid et al. 2004) were assessed in hippocampal cultures.
Application of bpV (50 nM; 30min) increased GluA1 surface
expression to 148 ± 8% of control (n = 36; P < 0.001; Fig. 2F). In
accordance with previous studies (Moult et al. 2010), leptin
resulted in a signiﬁcant increase in surface GluA1 labelling
(140 ± 7.2%; n = 36; P < 0.001; Fig. 2F). Similarly, GluA1 surface
expression was enhanced (to 167 ± 10% of control; n = 36;
P < 0.001) after exposure to leptin (116–130). Moreover, treat-
ment with bpV occluded the effects of either leptin or leptin
(116–130) such that GluA1 staining was 131 ± 6.6% and
148 ± 8.1% of control (n = 36; P < 0.001; for both; Fig. 2F) in the
presence of bpV and either leptin or leptin (116–130), respect-
ively. These data indicate that the ability of leptin (116–130) to
regulate GluA1 trafﬁcking involves inhibition of PTEN.
Leptin (116–130), But Not Leptin (22–56) Reverses Aβ1–42
Inhibition of Hippocampal Synaptic Plasticity
Several studies indicate that soluble Aβ oligomers impair
activity-dependent synaptic plasticity, as exposure to Aβ inhi-
bits hippocampal LTP (Shankar et al. 2008; Li et al. 2009) and
enhances LTD (Shankar et al. 2008). Moreover, our recent
studies indicate that leptin reverses the detrimental effects of
Aβ1–42 on both LTP and LTD (Doherty et al. 2013). Thus we
assessed if either of the fragments mirrored the protective
actions of leptin on hippocampal synaptic plasticity. Initially
we determined that application of leptin prevented the acute
effects of Aβ1–42 on LTP. In control slices, synaptic plasticity
was induced using high frequency stimulation (HFS; 100 Hz 10
trains of 8 stimuli) which increased synaptic transmission to
127 ± 3.4% of baseline (n =8; P < 0.01). Similarly in slices trea-
ted with the inactive peptide Aβ42–1 (1 μM; 40min), an
enhancement of synaptic transmission (132 ± 8.8% of base-
line) was induced (n = 5; P < 0.05; Fig. 3A). However, in accord-
ance with previous studies (Doherty et al. 2013), exposure to
Aβ1–42 not only blocked hippocampal synaptic plasticity
(96 ± 7.5% of baseline; n = 5; P > 0.05; Fig. 3A) but this effect
was reversed by leptin (25 nM; 135 ± 6.3% of baseline; n = 4;
P < 0.05; Fig. 3B). Similarly, treatment with 25 nM leptin (116–
130) before Aβ1–42 resulted in a robust increase in synaptic
transmission (to 136 ± 5.5% of baseline; n = 6; P < 0.05;
Fig. 3C). In contrast, HFS failed to increase synaptic efﬁcacy
(107 ± 3.3% of baseline; n = 5; P > 0.05) in slices exposed to
Aβ1–42 and leptin (22–56; Fig. 4D), although some STP was
observed. Thus these data indicate that like leptin, leptin
(116–130) prevents the detrimental effects of Aβ1–42 on hippo-
campal synaptic plasticity.
Leptin (116–130) Reverses Aβ1–42-Induced LTD
It is known that oligomeric Aβ promotes the induction of LTD
(Shankar et al. 2008) and that exposure to a low concentration
of leptin (10 nM) prevents facilitation of hippocampal LTD by
Aβ1–42 (Doherty et al. 2013). Thus we assessed if either of the
leptin fragments mirror leptin action. Initially we veriﬁed that
leptin prevented Aβ1–42-induced LTD. In agreement with previ-
ous studies (Doherty et al. 2013), application of the subthres-
hold LFS paradigm failed to induce LTD in vehicle-treated slices
(94 ± 5.6% of baseline; n = 5; P > 0.05), whereas robust LTD
(73 ± 3.8% of baseline; n = 5; P < 0.001) was induced in Aβ1–42-
treated slices (Fig. 4A). Furthermore, leptin (10 nM) reduced the
magnitude of Aβ1–42-induced LTD such that LFS depressed syn-
aptic transmission to 101 ± 5.3% of baseline in leptin-treated
slices (n = 4; P > 0.05; Fig. 4B). To establish if the leptin frag-
ments mirrored leptin action the effects of leptin (116–130) or
leptin (22–56) were also examined. Application of 10 nM leptin
(116–130) or leptin (22–56) had no signiﬁcant effect on basal
synaptic transmission (n = 6 for leptin [116–130] and n = 5 for
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leptin [22–56]). Application of 10 nM leptin (22–56) failed to alter
the magnitude of Aβ1–42-induced LTD such that synaptic trans-
mission was depressed to 73 ± 4.0% of baseline (n = 5; P < 0.001;
Fig. 4D). In contrast, a signiﬁcant reduction in the magnitude of
Aβ1–42-induced LTD (94 ± 5.2% of baseline; n = 5; P > 0.05;
Fig. 4C) was observed in hippocampal slices treated with leptin
(116–130; 10 nM; 45min) indicating that leptin (116–130) also
inhibits facilitation of LTD by Aβ1–42. Thus these data indicate
Figure 2. In adult, leptin (116–130) induces a persistent increase in synaptic efﬁcacy and increases GluA1 trafﬁcking to hippocampal synapses. (A) Pooled data showing that
application of leptin (116–130) results in a persistent increase in excitatory synaptic transmission in adult hippocampal slices. (B) In contrast application of leptin (22–56)
failed to alter excitatory synaptic strength. (C) Representative confocal images of surface GluR1 staining in control cultured hippocampal neurons and after exposure to lep-
tin, leptin (116–130) or leptin (22–56). Leptin (116–130) mirrors the effects of leptin by increasing GluA1 surface labelling. Scale bars, 10 μm. (D) Pooled data showing relative
changes in surface GluA1 labelling in control conditions, and after exposure to leptin, leptin (116–130) or leptin (22–56) in hippocampal neurons. (E) Pooled data of the per-
cent colocalization of surface GluA1 and synaptophysin immunolabelling in cultured hippocampal neurons. Leptin (116–130), but not leptin (22–56) increased GluA1 surface
labelling associated with synapses. (F) Pooled data of relative changes in surface GluA1 labelling in hippocampal cultures in control conditions, after bpV, leptin or leptin
(116–130) treatment, and in the presence of bpV and either leptin, or leptin (116–130). Inhibition of PTEN mimicked and occluded the effects of leptin (116–130).
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that leptin (116–130), but not leptin (22–56) reverses Aβ1–42-
induced facilitation of LTD.
Leptin (116–130) Prevents Aβ-Induced Internalization of
GluA1
Previous studies indicate that Aβ promotes internalization of the
AMPA receptor subunit, GluA1 (Hsieh et al. 2006; Liu et al. 2010);
an effect that is prevented by leptin (Doherty et al. 2013). To
determine if the leptin fragments mirror this effect, the cell sur-
face density of GluA1 was probed in cultured hippocampal neu-
rons (Moult et al. 2010). In accordance with previous studies
(Doherty et al. 2013), treatment with Aβ1–42 (500 nM; 20min) sig-
niﬁcantly attenuated (to 70 ± 2% of control) GluA1 surface
expression compared with control (Aβ42–1-treated) hippocampal
neurons (n = 48; P < 0.001; Fig. 4E). Application of a low concen-
tration of leptin (10 nM) induced a small increase in GluA1 sur-
face expression (113 ± 7% of control; n = 36; P < 0.01). However, in
leptin-treated neurons, Aβ1–42 failed to signiﬁcantly alter GluA1
surface expression (101 ± 4% of control; n = 36; P > 0.05). In con-
trast, treatment with a low concentration (10 nM) of leptin (22–
56) had no signiﬁcant effect on GluA1 trafﬁcking per se (n = 36;
P > 0.05). Moreover, leptin (22–56) failed to prevent the effects of
Aβ on GluA1 trafﬁcking as surface GluA1 was reduced to 51 ± 2%
of control (n = 36; P < 0.001) in the presence of Aβ and leptin (22–
56; Fig. 4E). Conversely, after exposure to leptin (116–130), Aβ1–42
failed to signiﬁcantly reduce GluA1 surface expression (97 ± 4%
of control; n = 36; P > 0.05). These data indicate that leptin (116–
130) mirrors leptin action by preventing Aβ1–42-induced internal-
ization of GluA1 in cultured hippocampal neurons.
Leptin (116–130) Prevents Copper and Aβ-Induced Cell
Death
We have demonstrated previously that leptin attenuates cortical
neuronal death triggered by Aβ1–42 or divalent copper ions
(Doherty et al. 2013). To determine whether leptin (116–130) has
neuroprotective actions, the effects of leptin (116–130) on the
viability of differentiated human neural cells (SH-SY5Y) was
examined after exposure to either 5 μΜ CuCl2 or 10 μM Aβ1–42.
Cells were treated with the toxin alone or with a range of con-
centrations (10–0.1 nM) of leptin or leptin (116–130).
Determination of membrane leakage by LDH assay revealed a
signiﬁcant reduction in LDH release after treatment with either
leptin or leptin (116–130; both 0.1–10nM). Thus for CuCl2-treated
cells, 10 nM leptin reduced LDH release by 39.5 ± 2.73%
Figure 3. Leptin (116–130) inhibits the aberrant effects of amyloid-β (Aβ)1–42 on hippocampal synaptic plasticity in juvenile slices. (A) Pooled data showing that HFS
(indicated by the arrow) induces synaptic plasticity in Aβ42–1-treated (open circles) slices, whereas Aβ1–42 inhibits synaptic plasticity (ﬁlled circles). (B) Exposure to lep-
tin prevented Aβ1–42-inhibition of synaptic plasticity. Treatment with leptin (116–130; C) but not leptin (22–56; D) reversed Aβ1–42-inhibition of synaptic plasticity.
Leptin (116–130) has Cognitive Enhancing and Neuroprotective Actions Malekizadeh et al. | 7
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
compared with CuCl2 alone (n = 5; P < 0.001; Fig. 5A); an effect
that was mirrored by 10nM leptin (116–130; 45.6 ± 2.92%Q8 [n = 5;
P < 0.001; Fig. 5A]). In Aβ1–42 treated cells, leptin also signiﬁcantly
reduced LDH release by 31.8 ± 13.2% (0.1 nM) and 47.9 ± 7.45%
(10 nM), respectively (n = 5; P < 0.001; Fig. 5B). Similarly, applica-
tion of 0.1nM or 10nM leptin (116–13) decreased LDH release by
26.7 ± 17.3% or 46.6 ± 9%, respectively (n = 5; P < 0.05; Fig. 5B).
Thus like leptin, treatment with leptin (116–130) reduces neur-
onal death in response to AD-linked toxins in vitro.
In parallel studies a crystal violet assay was used to verify
these ﬁndings by assessing cell number. In CuCl2-treated cells,
there was a concentration-dependent increase in the survival
Figure 4. Leptin (116–130) prevents Aβ-induced AMPA receptor internalization and facilitation of hippocampal LTD. (A) Pooled data showing that the subthreshold low
frequency stimulation (indicated by the arrow) failed to induce long-term depression (LTD) in Aβ42–1-treated (open circles) slices, whereas robust LTD (ﬁlled circles) is
induced in Aβ1–42-treated juvenile slices. (B) Exposure to leptin prevented Aβ1–42-induced LTD. Similarly treatment with leptin (116–130; C) but not leptin (22–56; D) pre-
vented Aβ1–42-induced LTD. E, Pooled data showing relative changes in GluA1 surface labelling in cultured hippocampal neurons in control (Aβ42–1) conditions and
after treatment with leptin, Aβ1–42, leptin (116–130), leptin (22–56) and in the presence of Aβ1–42 plus either leptin, leptin (116–130) or leptin (22–56), respectively. Leptin
and leptin (116–130) prevent Aβ-driven internalization of GluA1.
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of cells treated with either leptin or leptin (116–130). Thus,
treatment with leptin (0.1 nM) resulted in a 16.7 ± 3.4% increase
in cell number and this increased to 43.4 ± 9.2% in the presence
of 10 nM leptin (n = 5; P < 0.01). Similarly, exposure to 0.1 or
10 nM leptin (116–130) increased cell number by 27.8 ± 10.6%
and 39.9 ± 13.5%, respectively (n = 5; Fig. 5C). Treatment with
leptin (116–130) also mirrored leptin action by increasing cell
viability in Aβ1–42-treated cultures as cell number increased by
19.2 ± 15% and 44.3 ± 7.5% after treatment with 0.1 nM or 10 nM
leptin, respectively (n = 5 for each; P < 0.01). Exposure to leptin
(116–130) also resulted in signiﬁcant increases in cell number
(0.1 nM: 29.4 ± 9.4% increase; 10 nM: 51.8 ± 6.3% increase; n = 5
for both; P < 0.001; Fig. 5D).
As leptin (22–56) has biological activity in other systems, the
speciﬁcity of the leptin (116–130) fragment in promoting cell
survival was examined by determining whether leptin (22–56)
inhibited neuronal death induced by Aβ1–42. In contrast to leptin
(116–130), treatment with leptin (22–56) had no effect on the
viability of cells exposed to Aβ1–42 (41.2 ± 5.8% survival follow-
ing Aβ1–42 treatment and 48.6 ± 9.3% in Aβ1–42 with 10 nM leptin
(22–56) treated cells; n = 5; P > 0.5; data not shown). These data
reveal a potent neuroprotective effect of the leptin fragment
(116–130) that is comparable to the survival actions of leptin.
Moreover, this antiapoptotic response is speciﬁc to leptin (116–
130) as leptin (22–56) failed to inﬂuence neuronal viability.
The Neuroprotective Effects of Leptin (116–130) Involve
Activation of STAT3 and PI3-Kinase-Dependent
Signalling Pathways
Our previous studies indicate a crucial role for STAT3 and PI3-
kinase/Akt signalling in the neuroprotective actions of leptin
(Doherty et al. 2013). To determine whether leptin (116–130) acts
via similar signalling cascades we examined the effects of
pharmacological inhibitors of STAT3 (WP1066) or PI3-kinase
(wortmannin). In Aβ1–42-treated SH-SY5Y cells, application of
either inhibitor signiﬁcantly reduced the ability of leptin (116–130)
to alleviate neuronal death. When neurons were treated with the
STAT3 inhibitor, an 18.3 ± 3.2% increase in LDH release in leptin
(116–130) and Aβ1–42-treated cultures was observed, which is simi-
lar to the 26.7 ± 4.4% increase observed with Aβ1–42 alone (n = 5;
P > 0.5; Fig. 6A). Thus STAT3 inhibition blocks the neuroprotective
actions of leptin (116–130), suggesting a role for STAT3 in this pro-
cess. Furthermore, following inhibition of PI3-kinase with wort-
mannin an 26.9 ± 9.8% increase in LDH release was observed in
leptin (116–130) and Aβ1–42-treated cells which is not signiﬁcantly
different from cells treated with Aβ1–42 alone (n = 5; P > 0.5;
Fig. 6B). Thus these data also indicate a role for PI3-kinase in
mediating the neuroprotective actions of leptin (116–130).
To verify that leptin (116–130) directly activates these signal-
ling pathways, SH-SY5Y cells were exposed to 1 nM leptin (116–
130; 3 h) or left untreated prior to protein extraction for ELISA.
The ratio of phosphorylated STAT3 to pan STAT3 increased
markedly following leptin (116–130) administration (n = 3;
P < 0.01; Fig. 6C). Similarly an increase in the ratio of phos-
phorylated Akt to pan Akt was observed following exposure to
leptin (116–130; n = 3; P < 0.01; Fig. 6D). These data indicate that
leptin (116–130) reduces cell death by a mechanism involving
activation of STAT3 and PI3-kinase. Furthermore, exposure to
leptin (116–130) resulted in a signiﬁcant increase in the active
components of these signalling cascades.
Leptin (116–130) Enhances Episodic-Like Memory
The current data demonstrate that leptin (116–130) enhances
hippocampal synaptic plasticity mechanisms and has
Figure 5. Leptin (116–130) prevents copper and Aβ-induced cell death in human SH-SY5Y cells. (A) Pooled data revealing that leptin and leptin (116–130) prevent LDH
release induced by administration of 5 μM CuCl2. (B) Similar pooled data was obtained for cultures treated with 10 μM Aβ1–42. (C) Pooled data showing that in 5 μM
CuCl2 treated cultures enhanced numbers of cells are detected with a crystal violet assay when cultures are cotreated with either leptin or leptin (116–130) with a
similar trend observed when cultures were induced to die with 10 μM Aβ1–42 (D).
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neuroprotective effects. To further assess its therapeutic poten-
tial we next asked if this fragment has similar cognitive enhan-
cing properties to the whole leptin molecule. Previous studies
indicate that leptin enhances hippocampal-dependent memory
(Oomura et al. 2006; Farr et al. 2006), whereas resistance to lep-
tin results in impaired spatial memory (Li et al. 2002). We used
the object–place–context (OPC) recognition task which models
human episodic memory, the ﬁrst cognitive process to be com-
promised in the early stages of AD (Swainson et al. 2001).
Performance on this task has been shown to be impaired in
murine models of AD (Davis et al. 2013) and is compromised in
animals with lesions of hippocampus (Langston and Wood
2010) and lateral entorhinal cortex (Wilson et al. 2013). The task
is based on the object recognition paradigm and models the
integrated aspect of human episodic memory by exposing
rodents to novel combinations of objects, the spatial locations
in which they are experienced and the contextual features of
the environment (Fig. 7A; Eacott and Norman 2004). A total of
42 C57/BL6 mice were habituated to a testing environment and
then trained on object recognition, object–place recognition
and object–context recognition. Following training mice were
tested on 4 days of the episodic-like OPC task. On these days
mice were assigned to 1 of 3 groups (control, leptin, or frag-
ment) and on each day mice were given 100 µl IP injections of
saline, 7.8 nM/ml leptin, or 7.8 nM/ml leptin (116–130) 30min
prior to testing. One-way ANOVA on the discrimination indices
during the ﬁrst minute of the test phase revealed a signiﬁcant
effect of group (Fig. 7B; F(2,41) = 4.318, P = 0.02). Post hoc compar-
isons (Tukey’s HSD) revealed that both the leptin and leptin
(116–130) treated mice showed enhanced performance on the
task relative the control group (P < 0.05) and did not differ from
each other. One sample t-tests conﬁrmed that all groups per-
formed signiﬁcantly better than chance level performance
(P < 0.01). Finally analysis of the overall exploration time in
both sample and test phases of the task revealed no change in
total levels of exploration between groups demonstrating that
neither leptin nor leptin (116–130) produced a nonspeciﬁc
change in exploration behaviour (Fig. 7C; P > 0.05). The
increased discrimination index was driven by an increase in
exploration of the novel object combined with a decrease in the
exploration of the familiar object (Fig. 7D). Together these data
indicate that leptin (116–130) mirrors leptin’s action by enhan-
cing performance in episodic-like memory tasks.
Discussion
It is well established that the hormone leptin circulates in the
plasma and enters the brain via transport across the blood
brain barrier. In the hypothalamus, leptin plays a major role in
regulating food intake and body weight (Spiegelman and Flier
2001). However, the central actions of the hormone leptin are
not restricted to the hypothalamus and the regulation of
energy homeostasis. Indeed, a number of extrahypothalamic
brain regions, including the hippocampus display high levels of
leptin receptor expression (Irving and Harvey 2014). Leptin
mRNA and protein are also highly expressed in the hippocam-
pal formation (Morash et al. 1999) and emerging evidence sug-
gests brain-speciﬁc production of leptin (Eikelis et al. 2006).
Thus, it is likely that a combination of locally released leptin as
well as peripherally derived leptin reach hippocampal synapses
and can inﬂuence synaptic function. Indeed, numerous studies
indicate that leptin has potential cognitive enhancing proper-
ties as it readily facilitates the cellular events underlying hippo-
campal learning and memory. Thus, leptin has rapid effects on
activity-dependent synaptic plasticity, glutamate receptor traf-
ﬁcking and dendritic morphology (Irving and Harvey 2014).
Figure 6. The neuroprotective effects of leptin (116–130) involve activation of STAT3 and PI3-kinase-dependent signalling pathways. (A) Pooled data revealing that
treatmentQ9 of SH-SY5Y cells with the STAT-3 inhibitor WP1066 (5 μM) prevented leptin (116–130)-mediated neuroprotection from the effects of 10 μM Aβ1–42. (B) Pooled
data from LDH assays demonstrating that the PI3-kinase inhibitor wortmannin (50 nM) attenuated leptin (116–130)-mediated neuroprotection against 10 μM Aβ1–42. (C)
Pooled data from ELISA assays showing that leptin (116–130) stimulates phosphorylation of STAT3. (D) Pooled data from ELISA assays showing that leptin (116–130)
stimulates phosphorylation of Akt.
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In addition, several studies have identiﬁed neuroprotective
effects of leptin as the viability of central and peripheral neu-
rons is markedly inﬂuenced by this hormone (Weng et al. 2007;
Doherty et al. 2008; Guo et al. 2008). Recent clinical evidence
has established a link between circulating leptin levels and the
incidence of AD (Power et al. 2001; Lieb et al. 2009) that has
fuelled the possibility of using the leptin system as a novel
therapeutic target in AD. Indeed, treatment of various AD mod-
els with leptin prevents the detrimental effects of Aβ that occur
at both early and late stages of the disease (Fewlass et al. 2004;
Farr et al. 2006; Doherty et al. 2013). However, as leptin is a very
large peptide, developing small leptin-like molecules may be a
better therapeutic approach. Several fragments of the leptin
peptide are biologically active and mirror the antiobesity effects
of leptin (Grasso et al. 1997; Rozhavskaya-Arena et al. 2000;
Grasso et al. 2001). However, the cognitive enhancing and neu-
roprotective effects of the leptin fragments are not known.
Here we provide the ﬁrst compelling evidence that leptin (116–
130), but not leptin (22–56), has a potent effect on hippocampal
synaptic function as it promotes trafﬁcking of AMPA receptors
to synapses and facilitates hippocampal synaptic plasticity.
Moreover in cellular models that mimic amyloid toxicity, leptin
(116–130), but not leptin (22–56) prevents the aberrant effects of
Aβ on hippocampal synaptic function and neuronal viability.
These ﬁndings indicate that one particular leptin fragment,
namely (116–130), mirrors the beneﬁcial actions of leptin in pre-
venting the detrimental effects of Aβ at the early and late
stages of AD. Finally we have shown that the leptin fragment
that enhances hippocampal synaptic plasticity and has neuro-
protective effects, namely leptin (116–130), is also a cognitive
enhancer as it improves performance on tests of episodic
memory.
Here we show that, in accordance with previous studies
(Shanley et al. 2001; Wayner et al. 2004), NMDA receptor-
dependent synaptic plasticity is enhanced by leptin as treat-
ment with leptin promoted conversion of STP into a persistent
increase in synaptic transmission in juvenile hippocampal
slices. Similarly exposure to the leptin fragment (116–130) read-
ily facilitated synaptic plasticity as an increase in synaptic
strength was evident in leptin (116–130), but not leptin (22–56)-
treated slices. We have shown that the efﬁcacy of excitatory
synaptic transmission is also regulated by leptin in adult hippo-
campus (Moult et al. 2010). In agreement with this, application
of either leptin or leptin (116–130) to adult hippocampal slices
Figure 7. Leptin (116–130) enhances episodic-like memory. (A) Object–place–context task used to assess episodic-like memory. There are 2 sample phases in which
mice are exposed to different copies of 2 different objects (star and hexagon) and allowed to explore for 3min. In the test phase they see 2 new copies of 1 of the
objects. The arrow points to the object that has not been previously seen in that place within that context. (B) Mean ± SEM discrimination index for the 3 groups.
*P < 0.05. (C) Total exploration time in the test phase is not different between groups. (D) Exploration of the novel and familiar objects in the test phase.
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resulted in the induction of a persistent increase in synaptic
transmission. In contrast, however leptin (22–56) failed to alter
excitatory synaptic strength in adult hippocampus.
AMPA receptor trafﬁcking is pivotal for activity-dependent
synaptic plasticity (Collingridge et al. 2004) and leptin regulates
trafﬁcking of GluA1 to synapses (Moult et al. 2010). In this
study, treatment with either leptin or leptin (116–130) increased
GluA1 surface expression in cultured hippocampal neurons,
whereas leptin (22–56) was without effect. In colocalization
studies, the density of GluA1 subunits associated with synap-
ses was increased after application of leptin or leptin (116–130),
suggesting that leptin (116–130) parallels the actions of leptin
by boosting the synaptic insertion of AMPA receptors. We have
shown that leptin-driven trafﬁcking of GluA1 involves inhib-
ition of PTEN (Moult et al. 2010). Similarly in this study, the abil-
ity of leptin (116–130) to inﬂuence GluA1 trafﬁcking involves
inhibition of PTEN, as application of the PTEN inhibitor bpV
blocked the increase in GluA1 surface expression induced by
leptin (116–130) in hippocampal neurons. These data indicate
that like leptin, treatment with leptin (116–130) promotes
GluA1 trafﬁcking to hippocampal synapses via inhibition of
PTEN. Thus, overall these data indicate that the leptin fragment
(116–130) mirrors the actions of leptin as it markedly inﬂuences
the cellular events underlying learning and memory by regulat-
ing AMPA receptor trafﬁcking.
It is known that Aβ inhibits the induction of hippocampal
LTP (Shankar et al. 2008), and this detrimental effect of Aβ1–42 is
reversed by leptin (Doherty et al. 2013). Similarly, leptin (116–
130) reversed the acute effects of Aβ1–42 in this study as synap-
tic plasticity was readily induced in hippocampal slices
exposed to leptin (116–130) and Aβ1–42. Contrastingly, applica-
tion of leptin (22–56) failed to prevent the detrimental effects of
Aβ1–42 as no increase in synaptic strength was induced after
exposure to Aβ1–42 and leptin (22–56). However, in slices
exposed to leptin (22–56) post-tetanic potentiation (PTP) and
some STP was observed after HFS, suggesting that this frag-
ment may inﬂuence the transient enhancement of synaptic
strength induced by HFS. As PTP and STP are thought to involve
presynaptic expression mechanisms (Zucker and Regehr 2002;
Lauri et al. 2007), it is feasible that leptin (22–56) can act pre-
synaptically to inﬂuence glutamate release mechanisms.
Several studies indicate that Aβ1–42 also facilitates the induc-
tion of hippocampal LTD (Shankar et al. 2008; Li et al. 2009),
and this effect is also reversed by leptin (Doherty et al. 2013). In
accordance with these ﬁndings, treatment with leptin reduced
the magnitude of LTD in Aβ1–42-treated slices. Similarly, leptin
(116–130), but not leptin (22–56) attenuated the effects of Aβ1–42
as the magnitude of LTD was signiﬁcantly decreased in the
presence of leptin (116–130). Moreover, application of either lep-
tin or leptin (116–130) inhibited Aβ1–42-driven AMPA receptor
removal from hippocampal synapses, whereas treatment with
leptin (22–56) was without effect. Thus overall these data dem-
onstrate that leptin (116–130) mirrors the actions of leptin in
counteracting the detrimental acute effects of Aβ1–42 on hippo-
campal synaptic function.
Evidence is growing that leptin has neuroprotective actions
in various models of neurodegenerative disease. In Parkinson’s
disease models, treatment with leptin protects dopaminergic
neurons from various toxic insults (Weng et al. 2007; Doherty
et al. 2008), whereas in AD models of amyloid toxicity, leptin
increases neuronal viability via activation of STAT3 and PI3-
kinase signalling (Doherty et al. 2008; Guo et al. 2008; Doherty
et al. 2013). In this study, leptin and leptin (116–130) enhanced
the survival of human neural (SH-SY5Y) cells treated with
either Aβ1–42 or Cu2+. Conversely no change in cell viability was
evident after treatment with leptin (22–56), thereby providing
further evidence that leptin (116–130) but not leptin (22–56) mir-
rors the protective actions of leptin.
In these studies, we reveal that signalling via PI3-kinase and
STAT3 is essential for leptin (116–130)-mediated neuroprotec-
tion as selective inhibition of these pathways eliminated the
protective effects of leptin (116–130). Moreover, direct activation
of key components of PI3-kinase and STAT3 signalling path-
ways was observed following administration of leptin (116–
130). As stimulation of both PI3-kinase (Doherty et al. 2013;
Doherty et al. 2008) and STAT3 signalling cascades (Doherty
et al. 2013; Guo et al. 2008) mediate the neuroprotective actions
of leptin, these data indicate that leptin (116–130) is activating
the same signalling pathways as the full length leptin peptide
to induce neuronal survival. This provides further evidence
that leptin (116–130) is mirroring the neuronal effects of leptin.
These studies demonstrate that the 116–130 fragment of the
leptin molecule enhances hippocampal synaptic plasticity and
has neuroprotective effects. As such this fragment is a very
interesting therapeutic target to treat memory dysfunction and
protect against neurodegeneration in the early stages of AD. To
test the functional implications of the effects of leptin 116–130
we examined the effects of acute doses of this fragment on a
test of episodic-like memory. This test is particularly appropri-
ate as it models the type of memory that is ﬁrst compromised
in AD. Performance on the task has been shown to be impaired
in rodents with damage to the lateral entorhinal cortex (Wilson
et al. 2013), the ﬁrst region to be damaged in AD, and the hippo-
campus (Langston and Woods, 2010). It has also been shown
that the triple transgenic murine model of AD show impaired
performance on this task at 6 months of age (Davis et al. 2013).
The current data demonstrate powerful cognitive enhancing
effects of both leptin and leptin (116–130) as both groups per-
formed signiﬁcantly better than controls on the OPC task. This
is the ﬁrst time that leptin has been shown to enhance the spe-
ciﬁc type of memory that degrades in AD and the fact that this
cognitive enhancement is also produced by leptin (116–130)
suggests that this fragment is a viable tool to treat memory
dysfunction caused by damage to the hippocampal-entorhinal
network. Recent studies indicate that administration of leptin
also protects against Aβ-induced impairments in spatial mem-
ory tasks (Tong et al. 2015). Thus, it is feasible that administra-
tion of leptin (116–130) will also mirror the effects of leptin and
protect against the chronic effects of Aβ on hippocampal-
dependent learning and memory.
The current experiments demonstrated enhancement of
memory for object–place–context associations. Enhancement of
this hippocampal-dependent task is consistent with our ﬁnd-
ings showing enhancement of hippocampal synaptic plasticity
but it remains a possibility that leptin 116–130 may also
enhance simpler forms of recognition memory such as object
recognition or object–place recognition. These simpler forms of
recognition memory are dependent on other areas of the med-
ial temporal lobe network and so future work could examine
whether the cognitive enhancement is speciﬁc to the hippo-
campus or also affects the surrounding cortical inputs. One
other consideration is the anxiolytic properties of leptin that
have been reported in both normal (Liu et al. 2010) and chronic-
ally stressed rats (Lu et al. 2006). Reduced anxiety could poten-
tially affect performance on the spontaneous recognition tasks
as less anxious animals may explore more freely. This was not
found to be the case in the current study as the levels of explor-
ation in both sample and test phases of the OPC experiment
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were not different between groups. This is not surprising as
animals had extensive handling and pretraining before the OPC
test and so levels of anxiety would have been very low in all
animals.
In conclusion, these data indicate that the leptin (116–130)
fragment mirrors the cognitive enhancing effects of leptin as it
promotes trafﬁcking of the AMPA receptor subunit GluA1 to
synapses, facilitates hippocampal synaptic plasticity and
improves performance in an episodic-like memory task. In add-
ition, leptin (116–130) counteracts the detrimental effects of
Aβ1–42 on hippocampal synaptic function and neuronal viability
in various cellular models of amyloid toxicity. Our ﬁndings not
only reinforce the consensus that the leptin system is an
important therapeutic target in AD, but also establish that lep-
tin (116–130) may be useful in the development of leptin-
mimetic agents for therapeutic use.
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